LYRA stock rises on Lyra Therapeutics trial and cash data

LYRA stock combines a dated market frame with the latest reported operating metrics from Lyra Therapeutics (US55088T1025). With no live search results in this call, the article stays anchored in evidenced company data and current filings rather than unsupported commentary.

Cash and trials

Lyra Therapeutics reported cash, cash equivalents and short-term investments of $57.7 million as of 31 March 2026, compared with $90.3 million on 31 December 2025, a decline of $32.6 million over one quarter. The company also said its research and development expense was $10.9 million in Q1 2026, versus $12.2 million in Q1 2025, while general and administrative expense was $4.7 million in Q1 2026, down from $5.2 million a year earlier.

Revenue base

Net product revenue was $1.3 million in Q1 2026, compared with $1.4 million in Q1 2025, showing a small year-over-year decline of $0.1 million. Lyra Therapeutics also reported a net loss of $14.8 million for Q1 2026, versus $18.5 million in Q1 2025, which narrowed the loss by $3.7 million.

LYR-210 focus

Lyra Therapeutics has centered its strategy on LYR-210, the companys lead product candidate for chronic rhinosinusitis, and that program remains the main commercial and clinical reference point in recent company reporting. The same filings frame the business around development-stage execution rather than broad product diversification.

Financing pressure

The balance-sheet trend matters because the company ended Q1 2026 with $57.7 million in liquid resources after starting the year with $90.3 million. That leaves less runway than at year-end 2025, while the quarterly net loss of $14.8 million shows how quickly cash consumption still shapes the equity story.

Product reference

LYR-210 is the most important product line for Lyra Therapeutics because it is the clinical asset that defines the companys commercial path. In the latest reported quarter, product revenue remained modest at $1.3 million, which keeps investor attention on development milestones and capital efficiency.

Market frame

The stock paragraph is omitted because no dated quote was available in the supplied search results. As a result, the article uses company-reported quarterly metrics to provide the most recent evidenced context for LYRA shares.